nach oben

Erschienen in:

15.09.2020 | Original Contribution

Anthocyanins regulate serum adipsin and visfatin in patients with prediabetes or newly diagnosed diabetes: a randomized controlled trial

verfasst von: Liping Yang, Yun Qiu, Wenhua Ling, Zhaomin Liu, Lili Yang, Changyi Wang, Xiaolin Peng, Li Wang, Jianying Chen

Erschienen in: European Journal of Nutrition | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Epidemiological studies have suggested that adipsin and visfatin are associated with the development of type 2 diabetes. This is the first study to investigate the effects of supplementation with purified anthocyanins on serum adipsin and visfatin in patients with prediabetes or newly diagnosed diabetes.

Methods

A total of 160 participants with prediabetes or newly diagnosed diabetes (40–75 years old) were given 320 mg anthocyanins or placebo daily for 12 weeks in a randomized trial. Serum adipsin, serum visfatin, lipids and glycated hemoglobin A1c (HbA1c) were measured. The areas under the curve (AUCs) for glucose, insulin and C-peptide were determined before-and after-treatment by a standard 3-h 75 g oral glucose tolerance test (OGTT).

Results

Relatively significant increases in serum adipsin (net change 0.15 µg/mL [0.03, 0.27], p = 0.018) and decreases in visfatin (−3.5 ng/mL [−6.69, −0.31], p = 0.032) were observed between the anthocyanins and placebo groups. We also observed significant improvements in HbA1c (−0.11% [−0.22, −0.11], p = 0.033), apolipoprotein A-1 (apo A-1) (0.12 g/L [0.03, 0.21], p = 0.012) and apolipoprotein B (apo B) (−0.07 g/L [−0.14, −0.01], p = 0.033) in response to the anthocyanins intervention.

Conclusion

Purified anthocyanins supplementation for 12 weeks increased serum adipsin and decreased serum visfatin in patients with prediabetes or newly diagnosed diabetes.

Trial registration ClinicalTrials.gov, identifier: NCT02689765.

Nur mit Berechtigung zugänglich

Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R, Committee IDFDA (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract 157:107843. https://doi.org/10.1016/j.diabres.2019.107843CrossRefPubMed

Leal Vde O, Mafra D (2013) Adipokines in obesity. Clin Chim Acta 419:87–94. https://doi.org/10.1016/j.cca.2013.02.003CrossRefPubMed

Kim WK, Bae KH, Lee SC, Oh KJ (2019) The latest insights into adipokines in diabetes. J Clin Med 8(11):1874. https://doi.org/10.3390/jcm8111874CrossRefPubMedCentral

Lo JC, Ljubicic S, Leibiger B, Kern M, Leibiger IB, Moede T, Kelly ME, Chatterjee Bhowmick D, Murano I, Cohen P, Banks AS, Khandekar MJ, Dietrich A, Flier JS, Cinti S, Bluher M, Danial NN, Berggren PO, Spiegelman BM (2014) Adipsin is an adipokine that improves beta cell function in diabetes. Cell 158(1):41–53. https://doi.org/10.1016/j.cell.2014.06.005CrossRefPubMedPubMedCentral

Wang JS, Lee WJ, Lee IT, Lin SY, Lee WL, Liang KW, Sheu WH (2019) Association between serum adipsin levels and insulin resistance in subjects with various degrees of glucose intolerance. J Endoc Soc 3(2):403–410. https://doi.org/10.1210/js.2018-00359CrossRef

Zhou Q, Ge Q, Ding Y, Qu H, Wei H, Wu R, Yao L, Wei Q, Feng Z, Long J, Deng H (2018) Relationship between serum adipsin and the first phase of glucose-stimulated insulin secretion in individuals with different glucose tolerance. J Diabetes Invest 9(5):1128–1134. https://doi.org/10.1111/jdi.12819CrossRef

Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ (2006) Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91(1):295–299. https://doi.org/10.1210/jc.2005-1475CrossRefPubMed

Catalina MO, Redondo PC, Granados MP, Cantonero C, Sanchez-Collado J, Albarran L, Lopez JJ (2019) New insights into adipokines as potential biomarkers for type-2 diabetes mellitus. Curr Med Chem 26(22):4119–4144. https://doi.org/10.2174/0929867325666171205162248CrossRefPubMed

Wedick NM, Pan A, Cassidy A, Rimm EB, Sampson L, Rosner B, Willett W, Hu FB, Sun Q, van Dam RM (2012) Dietary flavonoid intakes and risk of type 2 diabetes in US men and women. Am J Clin Nutr 95(4):925–933. https://doi.org/10.3945/ajcn.111.028894CrossRefPubMedPubMedCentral

10.

Mursu J, Virtanen JK, Tuomainen TP, Nurmi T, Voutilainen S (2014) Intake of fruit, berries, and vegetables and risk of type 2 diabetes in Finnish men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Clin Nutr 99(2):328–333. https://doi.org/10.3945/ajcn.113.069641CrossRefPubMed

11.

Sasaki R, Nishimura N, Hoshino H, Isa Y, Kadowaki M, Ichi T, Tanaka A, Nishiumi S, Fukuda I, Ashida H, Horio F, Tsuda T (2007) Cyanidin 3-glucoside ameliorates hyperglycemia and insulin sensitivity due to downregulation of retinol binding protein 4 expression in diabetic mice. Biochem Pharmacol 74(11):1619–1627. https://doi.org/10.1016/j.bcp.2007.08.008CrossRefPubMed

12.

Tsuda T, Ueno Y, Aoki H, Koda T, Horio F, Takahashi N, Kawada T, Osawa T (2004) Anthocyanin enhances adipocytokine secretion and adipocyte-specific gene expression in isolated rat adipocytes. Biochem Biophys Res Commun 316(1):149–157. https://doi.org/10.1016/j.bbrc.2004.02.031CrossRefPubMed

13.

Matsukawa T, Inaguma T, Han J, Villareal MO, Isoda H (2015) Cyanidin-3-glucoside derived from black soybeans ameliorate type 2 diabetes through the induction of differentiation of preadipocytes into smaller and insulin-sensitive adipocytes. J Nutr Biochem 26(8):860–867. https://doi.org/10.1016/j.jnutbio.2015.03.006CrossRefPubMed

14.

American Diabetes A (2013) Standards of medical care in diabetes–2013. Diabetes Care 36(Suppl 1):S11–66. https://doi.org/10.2337/dc13-S011CrossRef

15.

Moher D (2011) CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Brit Med J 340:869CrossRef

16.

Cooke DN, Thomasset S, Boocock DJ, Schwarz M, Winterhalter P, Steward WP, Gescher AJ, Marczylo TH (2006) Development of analyses by high-performance liquid chromatography and liquid chromatography/tandem mass spectrometry of bilberry (Vaccinium myrtilus) anthocyanins in human plasma and urine. J Agric Food Chem 54(19):7009–7013. https://doi.org/10.1021/jf061562qCrossRefPubMed

17.

Nakamura Y, Matsumoto H, Morifuji M, Iida H, Takeuchi Y (2010) Development and validation of a liquid chromatography tandem mass spectrometry method for simultaneous determination of four anthocyanins in human plasma after black currant anthocyanins ingestion. J Agric Food Chem 58(2):1174–1179. https://doi.org/10.1021/jf9027365CrossRefPubMed

18.

Gomez-Banoy N, Guseh JS, Li G, Rubio-Navarro A, Chen T, Poirier B, Putzel G, Rosselot C, Pabon MA, Camporez JP, Bhambhani V, Hwang SJ, Yao C, Perry RJ, Mukherjee S, Larson MG, Levy D, Dow LE, Shulman GI, Dephoure N, Garcia-Ocana A, Hao M, Spiegelman BM, Ho JE, Lo JC (2019) Adipsin preserves beta cells in diabetic mice and associates with protection from type 2 diabetes in humans. Nat Med 25(11):1739–1747. https://doi.org/10.1038/s41591-019-0610-4CrossRefPubMedPubMedCentral

19.

Sayers SR, Beavil RL, Fine NHF, Huang GC, Choudhary P, Pacholarz KJ, Barran PE, Butterworth S, Mills CE, Cruickshank JK, Silvestre MP, Poppitt SD, McGill AT, Lavery GG, Hodson DJ, Caton PW (2020) Structure-functional changes in eNAMPT at high concentrations mediate mouse and human beta cell dysfunction in type 2 diabetes. Diabetologia 63(2):313–323. https://doi.org/10.1007/s00125-019-05029-yCrossRefPubMed

20.

Li D, Zhang Y, Liu Y, Sun R, Xia M (2015) Purified anthocyanin supplementation reduces dyslipidemia, enhances antioxidant capacity, and prevents insulin resistance in diabetic patients. J Nutr 145(4):742–748. https://doi.org/10.3945/jn.114.205674CrossRefPubMed

21.

Zhang PW, Chen FX, Li D, Ling WH, Guo HH (2015) A CONSORT-compliant, randomized, double-blind, placebo-controlled pilot trial of purified anthocyanin in patients with nonalcoholic fatty liver disease. Medicine 94(20):e758. https://doi.org/10.1097/MD.0000000000000758CrossRefPubMedPubMedCentral

22.

Anette Karlsen LR, Laake P, Paur I, Kjølsrud-Bøhn S, Sandvik L, Blomhoff AR (2007) Anthocyanins inhibit nuclear factor-kappaB activation in monocytes and reduce plasma concentrations of pro-inflammatory mediators in healthy adults. J Nutr 137:1951CrossRef

23.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419CrossRef

24.

Maturu A, DeWitt P, Kern PA, Rasouli N (2015) The triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio as a predictor of beta-cell function in African American women. Metabolism 64(5):561–565. https://doi.org/10.1016/j.metabol.2015.01.004CrossRefPubMed

25.

Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA (2006) Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes 55(5):1430–1435. https://doi.org/10.2337/db05-1200CrossRefPubMed

26.

Burattini R, Di Nardoa F, Casagrande F, Boemi M, Morosini P (2009) Insulin action and secretion in hypertension in the absence of metabolic syndrome: model-based assessment from oral glucose tolerance test. Metab Clin Exp 58(1):80–92. https://doi.org/10.1016/j.metabol.2008.08.010CrossRefPubMed

27.

Okuno Y, Komada H, Sakaguchi K, Nakamura T, Hashimoto N, Hirota Y, Ogawa W, Seino S (2013) Postprandial serum C-peptide to plasma glucose concentration ratio correlates with oral glucose tolerance test- and glucose clamp-based disposition indexes. Metabolism 62(10):1470–1476. https://doi.org/10.1016/j.metabol.2013.05.022CrossRefPubMed

28.

Vasilenko MA, Kirienkova EV, Skuratovskaia DA, Zatolokin PA, Mironyuk NI, Litvinova LS (2017) The role of production of adipsin and leptin in the development of insulin resistance in patients with abdominal obesity. Dokl Biochem Biophys 475(1):271–276. https://doi.org/10.1134/S160767291704010XCrossRefPubMed

29.

Martinez-Garcia MA, Moncayo S, Insenser M, Alvarez-Blasco F, Luque-Ramirez M, Escobar-Morreale HF (2019) Metabolic cytokines at fasting and during macronutrient challenges: influence of obesity, female androgen excess and sex. Nutrients 11(11):2566. https://doi.org/10.3390/nu11112566CrossRefPubMedCentral

30.

Saisho Y (2016) Postprandial C-peptide to glucose ratio as a marker of beta cell function: implication for the management of type 2 diabetes. Int J Mol Sci 17(5):744. https://doi.org/10.3390/ijms17050744CrossRefPubMedCentral

31.

Liu Y, Wang Y, Ni Y, Cheung CKY, Lam KSL, Wang Y, Xia Z, Ye D, Guo J, Tse MA, Panagiotou G, Xu A (2020) Gut microbiome fermentation determines the efficacy of exercise for diabetes prevention. Cell Metab 31(1):77–91. https://doi.org/10.1016/j.cmet.2019.11.001CrossRefPubMed

32.

Luc G, Empana JP, Morange P, Juhan-Vague I, Arveiler D, Ferrieres J, Amouyel P, Evans A, Kee F, Bingham A, Machez E, Ducimetiere P (2010) Adipocytokines and the risk of coronary heart disease in healthy middle aged men: the PRIME Study. Int J Obes 34(1):118–126. https://doi.org/10.1038/ijo.2009.204CrossRef

33.

Prugger C, Luc G, Haas B, Arveiler D, Machez E, Ferrieres J, Ruidavets JB, Bingham A, Montaye M, Amouyel P, Yarnell J, Kee F, Ducimetiere P, Empana JP, PRIME Study Group (2012) Adipocytokines and the risk of ischemic stroke: the PRIME Study. Ann Neurol 71(4):478–486. https://doi.org/10.1002/ana.22669CrossRefPubMed

34.

An JH, Kim DL, Lee TB, Kim KJ, Kim SH, Kim NH, Kim HY, Choi DS, Kim SG (2016) Effect of rubus occidentalis extract on metabolic parameters in subjects with prediabetes: a proof-of-concept, randomized, double-blind, placebo-controlled Clinical Trial. PTR. https://doi.org/10.1002/ptr.5664CrossRefPubMed

35.

Zhu Y, Xia M, Yang Y, Liu F, Li Z, Hao Y, Mi M, Jin T, Ling W (2011) Purified anthocyanin supplementation improves endothelial function via NO-cGMP activation in hypercholesterolemic individuals. Clin Chem 57(11):1524–1533. https://doi.org/10.1373/clinchem.2011.167361CrossRefPubMed

36.

Qin Y, Xia M, Ma J, Hao Y, Liu J, Mou H, Cao L, Ling W (2009) Anthocyanin supplementation improves serum LDL- and HDL-cholesterol concentrations associated with the inhibition of cholesteryl ester transfer protein in dyslipidemic subjects. Am J Clin Nutr 90(3):485–492. https://doi.org/10.3945/ajcn.2009.27814CrossRefPubMed

37.

Yang L, Ling W, Du Z, Chen Y, Li D, Deng S, Liu Z, Yang L (2017) Effects of anthocyanins on cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials. Adv Nutr 8(5):684–693. https://doi.org/10.3945/an.116.014852CrossRefPubMedPubMedCentral

38.

Owczarek AJ, Olszanecka-Glinianowicz M, Kocelak P, Bozentowicz-Wikarek M, Brzozowska A, Mossakowska M, Puzianowska-Kuznicka M, Grodzicki T, Wiecek A, Chudek J (2016) The relationship between circulating visfatin/nicotinamide phosphoribosyltransferase, obesity, inflammation and lipids profile in elderly population, determined by structural equation modeling. Scand J Clin Lab Invest 76(8):632–640. https://doi.org/10.1080/00365513.2016.1230884CrossRefPubMed

39.

Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ (2011) Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 27(6):515–527. https://doi.org/10.1002/dmrr.1201CrossRefPubMed

40.

Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, Milan G, Rossato M, Federspil G, Vettor R (2006) Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 91(8):3165–3170. https://doi.org/10.1210/jc.2006-0361CrossRefPubMed

41.

Hosseinzadeh-Attar MJ, Golpaie A, Foroughi M, Hosseinpanah F, Zahediasl S, Azizi F (2016) The relationship between visfatin and serum concentrations of C-reactive protein, interleukin 6 in patients with metabolic syndrome. J Endocrinol Invest 39(8):917–922. https://doi.org/10.1007/s40618-016-0457-1CrossRefPubMed

42.

Legakis I, Mantzouridis T, Bouboulis G, Chrousos GP (2016) Reciprocal changes of serum adispin and visfatin levels in patients with type 2 diabetes after an overnight fast. Arch Endocrinol Metab 60(1):76–78. https://doi.org/10.1590/2359-3997000000147CrossRefPubMed

43.

Ahmed MB, Ismail MI, Meki AR (2015) Relation of osteoprotegerin, visfatin and ghrelin to metabolic syndrome in type 2 diabetic patients. Int J Health Sci 9(2):127–139

44.

Toan NL, Van Hoan N, Cuong DV, Dung NV, Dung PT, Hang NT, Dieu DTH, Chung DT, Son HA, Phong PX, Lenon GB, Van De D, Van Tong H (2018) Adipose tissue-derived cytokines and their correlations with clinical characteristics in Vietnamese patients with type 2 diabetes mellitus. Diabetol Metab Synd 10:41. https://doi.org/10.1186/s13098-018-0343-4CrossRef

45.

Hetta HF, Ez-Eldeen ME, Mohamed GA, Gaber MA, ElBadre HM, Ahmed EA, Abdellatief RB, Abd-ElBaky RM, Elkady A, Nafee AM, Zahran AM, Ahmad M (2018) Visfatin serum levels in obese type 2 diabetic patients: relation to proinflammatory cytokines and insulin resistance. Egypt J Immunol 25(2):141–151PubMed

46.

Mazaherioun M, Hosseinzadeh-Attar MJ, Janani L, Vasheghani Farahani A, Rezvan N, Karbaschian Z, Hossein-Nezhad A (2012) Elevated serum visfatin levels in patients with acute myocardial infarction. Arch Iran Med 15(11):688–692PubMed

47.

Adya R, Tan BK, Chen J, Randeva HS (2008) Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation. Diabetes Care 31(4):758–760. https://doi.org/10.2337/dc07-1544CrossRefPubMed

48.

Zheng LY, Xu X, Wan RH, Xia S, Lu J, Huang Q (2019) Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes. Diabetol Metab Synd 11:60. https://doi.org/10.1186/s13098-019-0455-5CrossRef

49.

Yang W, Li Y, Wang JY, Han R, Wang L (2018) Circulating levels of adipose tissue-derived inflammatory factors in elderly diabetes patients with carotid atherosclerosis: a retrospective study. Cardiovasc Diabetol 17(1):75. https://doi.org/10.1186/s12933-018-0723-yCrossRefPubMedPubMedCentral

50.

McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volkova E, Kazmi K, Yusuf S, Investigators Is (2008) Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 372(9634):224–233CrossRef

51.

Emerging Risk Factors C, Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, Thompson A, Butterworth AS, Sarwar N, Wormser D, Saleheen D, Ballantyne CM, Psaty BM, Sundstrom J, Ridker PM, Nagel D, Gillum RF, Ford I, Ducimetiere P, Kiechl S, Koenig W, Dullaart RP, Assmann G, D’Agostino RB Sr, Dagenais GR, Cooper JA, Kromhout D, Onat A, Tipping RW, Gomez-de-la-Camara A, Rosengren A, Sutherland SE, Gallacher J, Fowkes FG, Casiglia E, Hofman A, Salomaa V, Barrett-Connor E, Clarke R, Brunner E, Jukema JW, Simons LA, Sandhu M, Wareham NJ, Khaw KT, Kauhanen J, Salonen JT, Howard WJ, Nordestgaard BG, Wood AM, Thompson SG, Boekholdt SM, Sattar N, Packard C, Gudnason V, Danesh J (2012) Lipid-related markers and cardiovascular disease prediction. JAMA 307(23):2499–2506. https://doi.org/10.1001/jama.2012.6571CrossRef

52.

Scazzocchio B, Vari R, Filesi C, D'Archivio M, Santangelo C, Giovannini C, Iacovelli A, Silecchia G, Li Volti G, Galvano F, Masella R (2011) Cyanidin-3-O-beta-glucoside and protocatechuic acid exert insulin-like effects by upregulating PPARgamma activity in human omental adipocytes. Diabetes 60(9):2234–2244. https://doi.org/10.2337/db10-1461CrossRefPubMedPubMedCentral

53.

Singh S, Netticadan T, Ramdath DD (2016) Expression of cardiac insulin signalling genes and proteins in rats fed a high-sucrose diet: effect of bilberry anthocyanin extract. Genes Nutr 11:8. https://doi.org/10.1186/s12263-016-0516-4CrossRefPubMedPubMedCentral

54.

Li Y, Zou W, Brestoff JR, Rohatgi N, Wu X, Atkinson JP, Harris CA, Teitelbaum SL (2019) Fat-produced adipsin regulates inflammatory arthritis. Cell Rep 27(10):2809–2816. https://doi.org/10.1016/j.celrep.2019.05.032CrossRefPubMedPubMedCentral

55.

McCullough RL, McMullen MR, Sheehan MM, Poulsen KL, Roychowdhury S, Chiang DJ, Pritchard MT, Caballeria J, Nagy LE (2018) Complement Factor D protects mice from ethanol-induced inflammation and liver injury. Am J Physiol Gastrointest Liver Physiol 315(1):G66–G79. https://doi.org/10.1152/ajpgi.00334.2017CrossRefPubMedPubMedCentral

56.

Saleh J, Al-Maqbali M, Abdel-Hadi D (2019) Role of complement and complement-related adipokines in regulation of energy metabolism and fat storage. Compr Physiol 9(4):1411–1429. https://doi.org/10.1002/cphy.c170037CrossRefPubMed

57.

Garten A, Schuster S, Penke M, Gorski T, de Giorgis T, Kiess W (2015) Physiological and pathophysiological roles of NAMPT and NAD metabolism. Nat Rev Endocrinol 11(9):535–546. https://doi.org/10.1038/nrendo.2015.117CrossRefPubMed

58.

Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307(5708):426–430. https://doi.org/10.1126/science.1097243CrossRefPubMed

59.

Kieswich J, Sayers SR, Silvestre MF, Harwood SM, Yaqoob MM, Caton PW (2016) Monomeric eNAMPT in the development of experimental diabetes in mice: a potential target for type 2 diabetes treatment. Diabetologia 59(11):2477–2486. https://doi.org/10.1007/s00125-016-4076-3CrossRefPubMedPubMedCentral

60.

Pei L, Wan T, Wang S, Ye M, Qiu Y, Jiang R, Pang N, Huang Y, Zhou Y, Jiang X, Ling W, Zhang Z, Yang L (2018) Cyanidin-3-O-beta-glucoside regulates the activation and the secretion of adipokines from brown adipose tissue and alleviates diet induced fatty liver. Biomed Pharmacother 105:625–632. https://doi.org/10.1016/j.biopha.2018.06.018CrossRefPubMed

Titel: Anthocyanins regulate serum adipsin and visfatin in patients with prediabetes or newly diagnosed diabetes: a randomized controlled trial
verfasst von: Liping Yang
Yun Qiu
Wenhua Ling
Zhaomin Liu
Lili Yang
Changyi Wang
Xiaolin Peng
Li Wang
Jianying Chen
Publikationsdatum: 15.09.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nutrition / Ausgabe 4/2021
Print ISSN: 1436-6207
Elektronische ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-020-02379-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Anthocyanins regulate serum adipsin and visfatin in patients with prediabetes or newly diagnosed diabetes: a randomized controlled trial